Caraco gets final FDA approval for generic Adipex

DETROIT Caraco Pharmaceuticals has been given final approval by the Food and Drug Administration for its application for the drug Phentermine Hydrochloride 37.5 mg, the generic of the short-term obesity management drug Adipex-P.

According to Caraco’s chief executive officer, Daniel H. Movens, the company is satisfied to receive the approval and is focusing "towards expanding our product line effectively, including products that are already available generically in the market that potentially can add measurable value."

For the twelve months ending June 2007, Phentermine HCl generic and brand drugs have had combined annual sales of about $34 million. The new generic will be released immediately and will bring Caraco’s product total to 36.